SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (1164)6/12/1997 1:38:00 AM
From: Vector1   of 9719
 
This is from Coulter's press release of about 1 month ago

--
Following Bexxar therapy, all 17 patients experienced a greater than 50 percent reduction of tumor
mass. Seven of these patients experienced complete responses (remissions with no detectable
cancer cells). Nine other patients were categorized as partial responses where tumor shrinkage was
still occurring. At the time of the presentation, one patient had relapsed. Side effects were
reversible and self-limiting, and included modest myelosuppression in all patients and 1-2 days of
flu-like syndrome (fever, headache, itching and muscle and joint pain) in seven patients.

----
7 complete remissions an all but one ongoing tumor shrinkage. These are very powerful results and substantially stronger than IDEC's product. Prob because the monoclonal antibody is conjugated to a radiopharma. Sound familiar CYTO fans. Market cap of about $125. Any thoughts.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News